In this episode, we will discuss the FDA's LDT final rule and the CAP’s ongoing advocacy efforts to protect pathologists and ensure patients have access to the tests they need for quality care.

In this CAPcast episode, Gladell Paner, MD, FCAP, discusses the renaming of low-grade prostate cancer with genitourinary pathologists Ming Zhou, MD, FCAP, and Rajal Shah, MD, FCAP. They explore the history, benefits, and challenges of removing the cancer label from Grade Group 1 prostate cancer and its potential impact on patient care, pathologist practices, and the broader healthcare system.

Dr. Alexis Peedin and Dr. Melissa George discuss blood bank lookbacks, which occur in the rare instances when unsuitable blood products are unknowingly collected and transfused.

Join Gladell Paner, MD, FCAP, as he delves into inherited cancer syndromes with surgical pathologist Vania Nosé, MD, FCAP, and oncologist Mark Lewis, MD, who is also a cancer survivor. Dr. Nosé explores the genetic and clinical aspects of multiple endocrine neoplasia type 1 (MEN1), while Dr. Lewis shares his personal journey with the condition.

Dr. Kalisha Hill and Dr. Kamran Mirza discuss how future pathologist champions are working to prevent a pathologist shortage by bringing medical students into the fold.

Dr. Diana Cardona and Dr. Harry Hwang explore format and verbiage changes that could make pathology reports work for both patients and other clinicians, without burdening pathologists.

CAP shares concerns that the FDA is moving forward with its plan for LDTs without making changes to ensure patient safety and access to accurate and innovative testing.

Gladell Paner, MD, FCAP, speaks with dermatopathologists Wonwoo Shon, DO, FCAP, and Christopher Kinonen, MD, MBA, FCAP. The group discusses the development of the CAP's new melanoma reporting templates, how they are used in testing, and what's on the horizon for biomarkers.

Since 1989, the CAP has led the way in developing new programs to ensure the quality and accuracy of laboratory testing for infectious diseases, including SARS CoV-2, Zika testing, and more.

The CAP’s Laboratory Preparedness Exercise helps laboratories assess and enhance their readiness for bioterrorism incidents, as well as natural emergencies, disasters, and other challenging situations.

The CAP 2024 Pathologists Leadership Summit featured the Spring House of Delegates meeting, educational courses, Advocacy programing, and our annual Hill Day.

Gladell Paner, MD, FCAP, speaks with Raja Seethala, MD, FCAP, and Nicole Cipriani, MD, FCAP, surgical pathologists specializing in head and neck pathology and members of the CAP Cancer Committee.

We’ll speak with Dr. Andres Romero about the Conrad 30 waiver program We’ll also review a boost to Medicare pay in the new spending bill, a hearing on LDTs, and more.

Three previous recipients of CAP Foundation grants and awards discuss the impact of the awards on their careers in pathology and involvement in the CAP.

In this episode, Gladell Paner, MD, FCAP, talks with gastrointestinal pathologists Dhanpat Jain, MD, FCAP, and Adam Booth, MD, FCAP, about how the CAP Biomarker Reporting Protocols were developed and used in practice.

Historic benchmarks earned by the CAP’s Pathologists Quality Registry, advocacy wins and strides in the private sector, changes to an FDA reclassification process and more

To commemorate World Cancer Day, Gladell Paner, MD, FCAP, chatted with M.E. de Baca, MD, FCAP, and Gail Vance, MD, FCAP, about how the CAP is addressing barriers to health equity through the Cancer Protocols, Council on Informatics and Pathology Innovation, and the CAP Foundation Global Pathology Committee.

This month we'll look at a prior authorization rule that could pave the way for legislation to reduce burdens on clinicians, a grant awarded to the CAP to improve healthcare communication, action on Medicare cuts, and more. We'll also sit down with Anna Tart, MD, FCAP, to talk about why the CAP no longer supports 'excited delirium' as an official cause of death.